Skip to main content
. 2019 May 27;38(13):e100532. doi: 10.15252/embj.2018100532

Figure EV2. Expression of P4HA2 is associated with poor prognosis in solid cancers.

Figure EV2

  1. Kaplan–Meier plots showing overall survival prognosis in breast cancer patients with high and low mRNA expression of TFPI2 and TIMP1 proteins revealed by proteomics study from extracted ECM produced by H1299RASSF1A lung cancer cells. Data show that breast cancer patients with high mRNA expression of TFPI2 and TIMP1 have better prognosis. The P values were derived from a log‐rank test.
  2. Clinical outcome and percentage of survival in patients across various cancers show effect of low versus high expression levels of mRNA P4HA2. Data collected from TCGA. The P values were derived from a log‐rank test.
  3. Quantification of fluorescence intensity of P4HA2 expression in H1299 cells with or without P4HA2 knockdown, 1.4DPCA treatment or combination of both. Bottom graph: Representative immunofluorescence images showing different expression of P4HA2 and collagen I in H1299control or H1299RASSF1A re‐expressing cells. Treatment of H1299control cells with siRNAP4HA2, P4HA inhibitor 1.4‐DPCA (inh.) or combination of both shows decreased collagen I expression. Scale bars: 10 μm.
  4. RT–PCR analysis of relative mRNA expression levels of P4HA2 in H1299 cells validating its after siP4HA2 knockdown.